These parameters comprise (1) MHC binding affinity, (2) MHC binding stability, or duration of peptide-MHC interaction, (3) agretopicity, or the ratio of mutant to wild-type binding affinity, (4) RNA transcript abundance within the tumor, and (5) foreignness, or homology to epitopes of known pathogens. The gene discussed is HLA-C; the disease is neoplasm.